{'fraction_non_alphanumeric': 0.025487256371814093, 'fraction_numerical': 0.019490254872563718, 'mean_word_length': 5.747474747474747, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tumour‐selective antivascular effects of the novel anti‐mitotic compound A‐318315: An in vivo rat regional haemodynamic study

1. It has been shown that tubulin‐binding agents can destabilize cellular microtubules and suppress tumour growth; but it has also become apparent that some compounds can exert anti‐vascular effects within the neovasculature of a solid tumour. To date, the difficulty with these targets has been the ability to selectivity induce vascular damage to the tumour while leaving normal vasculature unaffected. The data presented here characterizes the in vivo, tumour selective, anti‐vascular effects of the novel tubulin‐binding agent A‐318315.